DE69916811D1 - Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden - Google Patents

Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden

Info

Publication number
DE69916811D1
DE69916811D1 DE69916811T DE69916811T DE69916811D1 DE 69916811 D1 DE69916811 D1 DE 69916811D1 DE 69916811 T DE69916811 T DE 69916811T DE 69916811 T DE69916811 T DE 69916811T DE 69916811 D1 DE69916811 D1 DE 69916811D1
Authority
DE
Germany
Prior art keywords
glp
micella
aggregates
derivatives
content over
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69916811T
Other languages
English (en)
Other versions
DE69916811T2 (de
Inventor
Bjerre Knudsen
Olaf Huusfeldt
Franklin Nielsen
C Kaarsholm
Birk Olsen
Erik Bjorn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of DE69916811D1 publication Critical patent/DE69916811D1/de
Application granted granted Critical
Publication of DE69916811T2 publication Critical patent/DE69916811T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
  • Disintegrating Or Milling (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69916811T 1998-02-27 1999-02-25 Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden Expired - Lifetime DE69916811T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK26898 1998-02-27
DK27298 1998-02-27
DK27298 1998-02-27
DK26898 1998-02-27
PCT/DK1999/000084 WO1999043341A1 (en) 1998-02-27 1999-02-25 Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates

Publications (2)

Publication Number Publication Date
DE69916811D1 true DE69916811D1 (de) 2004-06-03
DE69916811T2 DE69916811T2 (de) 2005-04-14

Family

ID=26063652

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69916811T Expired - Lifetime DE69916811T2 (de) 1998-02-27 1999-02-25 Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden

Country Status (6)

Country Link
EP (1) EP1061946B1 (de)
JP (1) JP2002504518A (de)
AT (1) ATE265224T1 (de)
AU (1) AU2610799A (de)
DE (1) DE69916811T2 (de)
WO (1) WO1999043341A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE493998T1 (de) 1996-08-08 2011-01-15 Amylin Pharmaceuticals Inc Pharmazeutische zusammensetzung mit einem exendin-4-peptid
EP1250126A2 (de) * 2000-01-11 2002-10-23 Novo Nordisk A/S Transepitheliale verabreichung von derivaten von glp-1
EP1634605A3 (de) 2000-03-08 2006-10-11 Novo Nordisk A/S Behandlung von Dyslipämie bei einem Patienten mit Typ 2 Diabetes
EP1294757B1 (de) 2000-06-16 2006-11-22 Eli Lilly And Company Analoge des glucagon ähnlichen peptid-1
WO2002043709A1 (fr) 2000-12-01 2002-06-06 Takeda Chemical Industries, Ltd. Procede de production d'une preparation contenant une substance bioactive
CA2716959A1 (en) * 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
ATE382057T1 (de) * 2001-06-28 2008-01-15 Novo Nordisk As Stabile formulierung von modifiziertem glp-1
CN1363654A (zh) * 2001-07-19 2002-08-14 上海华谊生物技术有限公司 生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法
CA2458371A1 (en) 2001-08-23 2003-03-06 Eli Lilly And Company Glucagon-like peptide-1 analogs
KR101198346B1 (ko) 2003-04-08 2012-11-06 노보 노르디스크 에이/에스 크로마토그래피 고정상의 재생
WO2004089985A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
PL1633391T3 (pl) 2003-06-03 2012-03-30 Novo Nordisk As Stabilizowane farmaceutycznie kompozycje peptydowe
JP4936884B2 (ja) 2003-06-03 2012-05-23 ノボ・ノルデイスク・エー／エス 安定化された薬学的ペプチド組成物
WO2005028516A2 (en) * 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
US20070203058A1 (en) * 2003-09-19 2007-08-30 Novo Nordisk A/S Novel Glp-1 Derivatives
HUE038395T2 (hu) 2003-11-20 2018-10-29 Novo Nordisk As Propilén-glikol tartalmú peptidkészítmények, amelyek elõállításra és injekciós eszközökben történõ alkalmazásra optimálisak
JP4865565B2 (ja) 2003-12-09 2012-02-01 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニストを用いた食物選択の制御
TWI353250B (en) 2003-12-16 2011-12-01 Ipsen Pharma Sas Glp-1 pharmaceutical compositions
JP2008501765A (ja) 2004-06-11 2008-01-24 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−１アゴニストを用いた薬剤誘発性肥満の中和
JP4965446B2 (ja) 2004-08-31 2012-07-04 ノヴォ ノルディスク アー／エス ペプチド、ポリペプチド及びタンパク質の安定化のためのトリス（ヒドロキシメチル）アミノメタンの使用
JP5107713B2 (ja) 2004-10-07 2012-12-26 ノヴォ ノルディスク アー／エス 遅延性のエキセンディン−４化合物
EP1799710A2 (de) 2004-10-07 2007-06-27 Novo Nordisk A/S Glp-1 verbindungen mit verlängerter wirkdauer
AU2005303777B2 (en) 2004-11-12 2010-12-16 Novo Nordisk A/S Stable formulations of insulinotropic peptides
EP1863521B1 (de) 2005-03-18 2014-05-07 Novo Nordisk A/S Erweiterte glp-1-verbindungen
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
JP5977945B2 (ja) 2008-08-06 2016-08-24 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 長期のインビボ有効性を有するコンジュゲートタンパク質
ES2542202T3 (es) 2009-01-22 2015-08-03 Novo Nordisk Health Care Ag Compuestos de hormonas de crecimiento estables
JP6086528B2 (ja) 2009-08-06 2017-03-01 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 長期のインビボ有効性を有する成長ホルモン
JP5875527B2 (ja) 2010-01-22 2016-03-02 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー ｉｎ−ｖｉｖｏにおける効力が延長された成長ホルモン
AU2011208620B2 (en) 2010-01-22 2015-04-16 Novo Nordisk Health Care Ag Stable growth hormone compounds
WO2011123943A1 (en) 2010-04-09 2011-10-13 Mount Sinai Hospital Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
CA2793715A1 (en) 2010-04-30 2011-11-03 Sanwa Kagaku Kenkyusho Co., Ltd. Peptide for improving in vivo stability of physiologically active substance or the like and physiologically active substance with improved in vivo stability
RS56998B1 (sr) 2010-12-16 2018-05-31 Novo Nordisk As Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
WO2013139694A1 (en) 2012-03-22 2013-09-26 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
CN104203221A (zh) 2012-03-22 2014-12-10 诺和诺德A/S（股份有限公司） 包含递送剂的组合物及其制备
US20150157619A1 (en) 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
WO2014060472A1 (en) 2012-10-17 2014-04-24 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
JP6464145B2 (ja) 2013-04-05 2019-02-06 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 成長ホルモン化合物製剤
ES2630106T3 (es) 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
AU2016335287A1 (en) 2015-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
TWI762706B (zh) 2017-08-24 2022-05-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
KR102647171B1 (ko) 2018-02-02 2024-03-15 노보 노르디스크 에이/에스 Glp-1 작용제 및 n-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 고형 조성물
JP7442823B2 (ja) 2018-04-06 2024-03-05 シプルメット・ゲーエムベーハー 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
AU2019410643A1 (en) 2018-12-21 2021-08-12 Jiangsu Hengrui Medicine Co., Ltd. Bispecific protein
BR112022013795A2 (pt) 2020-02-18 2022-09-13 Novo Nordisk As Composição farmacêutica líquida, e, kit
WO2021219710A1 (en) 2020-04-29 2021-11-04 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and histidine
EP4210680A1 (de) 2020-09-07 2023-07-19 Cyprumed GmbH Verbesserte pharmazeutische formulierungen von glp-1-rezeptoragonisten
CN115925994B (zh) 2020-09-30 2023-09-22 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
WO2024141760A1 (en) 2022-12-30 2024-07-04 Algipharma As Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration
CN116730902B (zh) * 2023-08-07 2023-11-21 杭州湃肽生化科技有限公司 一种合成利拉鲁肽的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
DE3750402T3 (de) * 1986-05-05 1997-04-10 Gen Hospital Corp Insulinotropes hormon.
ATE193541T1 (de) * 1989-03-20 2000-06-15 Gen Hospital Corp Insulinotropes hormon
CA2073856C (en) * 1990-01-24 2002-12-03 Douglas I. Buckley Glp-1 analogs useful for diabetes treatment
JP3149958B2 (ja) * 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体

Also Published As

Publication number Publication date
ATE265224T1 (de) 2004-05-15
EP1061946B1 (de) 2004-04-28
AU2610799A (en) 1999-09-15
EP1061946A1 (de) 2000-12-27
DE69916811T2 (de) 2005-04-14
JP2002504518A (ja) 2002-02-12
WO1999043341A1 (en) 1999-09-02

Similar Documents

Publication Publication Date Title
DE69916811D1 (de) Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden
WO1999043361A8 (en) Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
WO1999006545A3 (en) Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation
EE9500034A (et) Oksalüülaminobensofuraan- ja -bensotienüülderivaadid, nende valmistamismeetod ja kasutamine
BR0212968A (pt) Composição farmacêutica, composto, e, método para tratar ou prevenir condições mediadas pelo ccr2, mcp-1 ou pela interação destes
CA2352625A1 (en) Cleavable solid dosage forms and method for the production thereof
WO2003037271A3 (en) Compounds, pharmaceutical compositions and methods of use therefor
HUP9900936A1 (hu) Izocianátalapú készítmények, bevonatként történő alkalmazásuk és az így előállított bevonatok
BR0010952A (pt) Material de revestimento com uma mistura de ácidos silìcicos e uréia e/ou derivados de uréia
WO2001070664A3 (en) Lipoxin analogs and methods for the treatment of periodontal disease
HK1058934A1 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
NO20071498L (no) Substituerte acylhydroksamsyrer samt fremgangsmate for a redusere TNFa-nivaet
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
DK1401948T3 (da) Additiv-funktionaliserede organofile nanoskalerede fyldstoffer
ATE253063T1 (de) 5-ht1f-agonisten
MY127953A (en) Gabapentin-containing solid compositions and process for preparing the same
ES2068803T1 (es) Aditivo para evitar la corrosion de metales en materiales de construccion, procedimiento para la fabricacion de materiales de construccion utilizando el inhibidor de corrosion y materiales de construccion que contienen el inhibidor de corrosion.
ATE413388T1 (de) Muskarin antagonisten
DE69712084D1 (de) Aminothiazole derivate, ihre herstellung und sie enthaltenden pharmazeutischen zusammensetzungen
EE9800022A (et) Karbapeneemühend, selle stabiliseerimismeetod ja stabiliseeritud vorm ning farmatseutiline kompositsioon
EA200300066A1 (ru) Производные аминоалкоксибензоил-бензофурана или бензотиофена, способ их получения и содержащие их композиции
ATE229518T1 (de) Cis-3,4-chromanderivate zur vorbeugung oder behandlungvon oestrogenbezogenen krankheiten oder syndromen
ES2178209T3 (es) Procedimiento para preparar una composicion de asfalto.
IS2611B (is) Fullkomið fóður fyrir fiskseiði og aðferð til að búa það til
BG106748A (en) Method and compositions for treating pulmonary diseases

Legal Events

Date Code Title Description
8364 No opposition during term of opposition